Regeneron Pharmaceuticals Inc (REGN) Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release
43 articles, transcripts, and reports
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Corporate Conference
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Q4 2025 Earnings Conference
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Corporate Conference
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Corporate Conference
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release